Sysmex Corporation (TYO:6869)

Market Cap	873.70B -48.0%
Revenue (ttm)	502.95B +0.2%
Net Income	44.75B -22.6%
EPS	71.77 -22.5%
Shares Out	623.18M
PE Ratio	19.53
Forward PE	18.78
Dividend	36.00 (2.57%)
Ex-Dividend Date	Mar 30, 2026

Volume	3,470,600
Average Volume	5,445,615
Open	1,376.50
Previous Close	1,365.00
Day's Range	1,366.50 - 1,409.00
52-Week Range	1,268.00 - 2,933.50
Beta	0.66
RSI	48.51
Earnings Date	May 8, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.